Search Results for 'hiv phase'
hiv phase published presentations and documents on DocSlides.
Regulatory issues in HIV cure Research
by debby-jeon
HIV Cure Research Training Curriculum. Regulatory...
The Revolution of mRNA Vaccines: Implications for an HIV Vaccine
by carny
Richard A. . Koup. , MD. Acting Director. Vaccine ...
Roy M. Gulick, MD, MPH Rochelle Belfer Professor in Medicine
by trish-goza
Weill Cornell Medicine. New York, New York. Inves...
Phase 2 of new ARVs Fostemsavir
by conchita-marotz
, . prodrug. of . temsavir. . (attachment inhib...
Long Acting ART for Treatment and
by tatyana-admore
PrEP. Anton Pozniak . MD FRCP. Consultant Physici...
Roy M. Gulick, MD, MPH Rochelle Belfer Professor in Medicine
by debby-jeon
Weill Cornell Medicine. New York, New York. Inves...
New Prevention Technologies Workshop
by sherrill-nordquist
Module 3: Overview of Prevention Research. www.ic...
Solent Sexual Health Services - Overview
by jiraiya471
October 2022. Clare Scholfield - Clinical Director...
New and Investigational ART Drugs and Strategies
by elina
Judith S. Currier, MD, . MSc. Division of Infectio...
Immunoglobulin Classes and Acute Phase Proteins In
by murphy
The Breast Milk and Plasma of Nigerian HIV-Infecte...
Joseph J. Eron, Jr, MD Professor of Medicine and Epidemiology
by Hulksmash
The University of North Carolina at Chapel Hill. C...
A Phase I/II Trial of the Pharmacokinetics, Tolerability, and Safety of Once-Weekly Rifapentine and
by warlikebikers
IMPAACT . 2001 STUDY . Mhembere T.P. (B. Pharm . (...
Rectal Mucosa Ian McGowan MD DPhil FRCP
by marina-yarberry
University of Pittsburgh, PA, USA. 21. st. July,...
What’s Next – and When:
by sherrill-nordquist
An Update on Injectable . P. revention. Alex R Ri...
ART for Prevention… What Happens Next?
by briana-ranney
Myron S. Cohen, MD. Yeargan-Bate Eminent Professo...
A two-arm (proof of concept) randomised phase II trial Vorinostat plus a prime boost Vaccine
by alexa-scheidler
A-899-0059-12977. Presented by Professor Sarah Fi...
Long Acting Injectable Agents for HIV Prevention
by giovanna-bartolotta
Nyaradzo M Mgodi (. MBChB. , . MMed. ). On behalf...
Recalibrating the EID Cascade in Zimbabwe
by mitsue-stanley
True outcomes among a sample of HIV-exposed infan...
Getting Outside of the Box: Designing and Implementing Inno
by lindy-dunigan
Willo Pequegnat, Ph.D., Salix Health Consulting/U...
State of the Field Exploring 2015’s Top Ten List for the HIV Prevention Research Field
by brooke
Manju Chatani, Stacey Hannah, Mitchell Warren. Thu...
ALL, Acute lymphoblastic leukemia;
by HappyHippo
BCMA, B-cell maturation antigen; DLBCL, diffuse la...
SASA Mobilizing Communities to End Violence against Women and HIVAID
by jordyn
(Uganda)
SASA! is a
programme
developed by Raisi...
Reaching UNGA HLM on TB targets for ending TB in children and adolesce
by garboardcola
First Paediatric Antituberculosis Drug Optimizatio...
C-EDGE Co-Infected: Phase 3 Study of
by giovanna-bartolotta
C-EDGE Co-Infected: Phase 3 Study of Grazoprevi...
Safety , Tolerability, and Pharmacokinetics of Long-Acting Injectable
by phoebe-click
Cabotegravir. in Low-Risk . HIV-uninfected . Wom...
Routine use of point-of-care early infant diagnosis testing in Côte d’Ivoire:
by tatiana-dople
Early lessons learnt. Patricia . Fassinou . Ekou...
Tuberculosis Trials Consortium Study 31
by stefany-barnette
AIDS Clinical Trials Group A5349. Rifapentine-con...
Hanneke Schuitemaker VP, Head Viral Vaccine Discovery and Translational Medicine, Janssen Vaccines
by debby-jeon
Professor in Virology at the Academic Medical Cen...
Project Steering Committee Meeting
by pamella-moone
Colombo, 2012. RAS/H13: Prevention of transmissio...
Roy M. Gulick, MD, MPH Gladys and Roland Harriman Professor of Medicine
by luanne-stotts
Chief, Division of Infectious Diseases. Weill Med...
